News

VANCOUVER, Wash., US and OXFORD, UK, December 20, 2023 — Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs.

New Scientist, in association with SRG, is conducting a global salary, employment and industry survey (Life Sciences, Clinical & Engineering) to provide you with the latest insights into your salary. The results of this survey benchmarking salary will be published on the SRG website. Be part of the conversation and participate today!

 
London, 18th December 2023 - Kadans Science Partner (“Kadans”) has added a new asset in King’s Cross, London, UK to its Pan-European portfolio. The new asset at 22-23 Tileyard Road will be delivered as purpose built, high-quality laboratory accommodation, providing much needed technical real estate to the King’s Cross and London market. The asset was acquired from City & Provincial Properties. This latest acquisition continues to grow Kadans’ footprint in the Knowledge Quarter, London, a global centre of excellence for science & technology innovation.

OXFORD, BRISTOL, EDINBURGH, UK – 15 December 2023 – Leading computational biology company PrecisionLife®, which is driving precision medicine in complex chronic diseases, the ME/CFS charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh have been awarded a £622,000 grant by Innovate UK's Advancing Precision Medicine programme to improve diagnosis and treatment for the millions of people affected by ME/CFS and long Covid.